Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma (Q73356015)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

S Gauthier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

E Pujade-Lauraine

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

T Facchini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M J Goudier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

I Krakowski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

G Netter-Pinon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Frenay

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

C Gousset

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

F N Marié

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Benmiloud

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1471-1476

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Clinical trials of P-glycoprotein reversal in solid tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

MDR1 gene expression in solid tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

P-glycoprotein expression in treated and untreated human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Reversal of drug-resistance in multiple myeloma with verapamil.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Does verapamil help overcome multidrug resistance in tumor cell lines and cancer patients?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026556119020

7 January 2021

Identifiers

DOI

10.1023/A:1026556119020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142488%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference